Last updated on August 2018

A Phase 2 clinical study for patients with Squamous Cell Carcinoma of the Head and Neck

Brief description of study

The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Clinical Study Identifier: NCT02499120

Contact Investigators or Research Sites near you

Start Over

State Budgetary Healthcare Institution "Oncology Center #2" of the Ministry of
Sochi, Russian Federation